insights_auto
Why is BH3 down 2,07%?
Dive Deeperchevron_right
BH3:FRA
PTC Therapeutics, Inc.
€55,84
arrow_downward
-2,07%(-1,18) 1D
2 ຕ.ລ., 22 ໂມງ 0 ນາທີ 00 ວິນາທີ GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BH3...
Open
€56,20
High
€56,20
Low
€55,84
Mkt. cap
5,30 ຕື້
Avg. vol.
0,00
Volume
0,00
52-wk high
€77,02
52-wk low
€51,00
No. of employees
991
Open
€56,20
High
€56,20
Low
€55,84
Mkt. cap
5,30 ຕື້
Avg. vol.
0,00
Volume
0,00
52-wk high
€77,02
52-wk low
€51,00
No. of employees
991
News stories
From web sources and news partners
MarketBeat
·
11 ຊົ່ວໂມງກ່ອນ
PTC Therapeutics (NASDAQ:PTCT) Director Sells $781,920.00 in Stock
Stock Titan
·
13 ຊົ່ວໂມງກ່ອນ
After exercising options at $11.23, a director sold 12,000 PTC Therapeutics (PTCT) shares at $65.16.
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
Founded1 ມ.ກ. 1998
HeadquartersWarren, ນິວເຈີຊີ, ສະຫະລັດ
SectorBiotechnology
Websiteptcbio.com